Summarized by Masters of Longevity from PR Newswire.
LEADER real-world analysis found 76% lower dementia progression through 36 months.

Key Takeaways
- Leqembi-treated patients showed a 76% lower progression rate.
- Ninety-one point seven percent remained on Leqembi at 18 months.
- Real-world evidence was subject to bias and data inconsistency.



